ArticleCancers2021
Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02759835 (A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer), which is not on this map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Circulating extracellular vesicle PTPRO methylation: an exploratory biomarker for minimally invasive diagnosis of early-stage lung adenocarcinoma.Cancer cell international · 2026Article
- Salivary biomarkers in oral cancer diagnosis: advancing conventional treatment strategies.Military Medical Research · 2026Review
- Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study.JTO clinical and research reports · 2025Article
- Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology.NPJ precision oncology · 2025Review
- Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics.Cancers · 2025Review
- Exosomes in early lung cancer diagnostics: the current state of progress made and prospects.Frontiers in cell and developmental biology · 2025Review
- Liquid-based biomarkers in breast cancer: looking beyond the blood.Journal of translational medicine · 2023Review
- Saliva diagnostics: Salivaomics, saliva exosomics, and saliva liquid biopsy.Journal of the American Dental Association (1939) · 2023Review
- Article
- Single-Droplet Microsensor for Ultra-Short Circulating EFGR Mutation Detection in Lung Cancer Based on Multiplex EFIRM Liquid Biopsy.International journal of molecular sciences · 2023Article
- Isolation of salivary cell-free DNA for cancer detection.PloS one · 2023Article
- Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing.Journal of personalized medicine · 2022Review
- Saliva Diagnostics.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022Review
- The prognostic influence of histological subtypes of micropapillary tumors on patients with lung adenocarcinoma ≤ 2 cm.Frontiers in oncology · 2022Article
- The emerging potentials of lncRNA DRAIC in human cancers.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 3 institutions in 1 country.
Chul KimThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Liqiang XiLaboratory of Pathology, CCR, NCI, NIH, Bethesda, MD 20892, USA.ORCID 0000-0001-5033-7072
Constance M CultraroThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Fang WeiSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA 90024, USA.
Gregory JonesInivata, Cambridge CB21 6GS, UK.
Jordan ChengSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA 90024, USA.
Ahmad ShafieiRadiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-5038-161X
Trinh Hoc-Tran PhamLaboratory of Pathology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Nitin RoperThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Elizabeth AkothThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Azam GhafoorThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Vikram MisraThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Nina MonkashThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Charles StromLiquid Diagnostics LLC, San Clemente, CA 92673, USA.
Michael TuLiquid Diagnostics LLC, San Clemente, CA 92673, USA.ORCID 0000-0002-7227-4030
Wei LiaoEZLife Bio Inc., Los Angeles, CA 91324, USA.
David ChiaDepartment of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA 90095, USA.
Clive MorrisInivata, Cambridge CB21 6GS, UK.
Seth M SteinbergBiostatistics and Data Management Section, NCI, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-8280-551X
Hadi BagheriRadiology and Imaging Sciences, Clinical Center, NIH, Bethesda, MD 20892, USA.
David T W WongSchool of Dentistry, University of California, Los Angeles, Los Angeles, CA 90024, USA.ORCID 0000-0002-0290-2206
Mark RaffeldLaboratory of Pathology, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Udayan GuhaThoracic and GI Malignancies Branch, CCR, NCI, NIH, Bethesda, MD 20892, USA.
Center for Cancer Research · USUniversity of California, Los Angeles · USNational Institutes of Health Clinical Center · US
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5MMolecular Diagnostics Core LaboratoryZICBC011079 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI XI, LIQIANG · 2009 to 2025
$33.8MEFIRM Liquid Biopsy Research Laboratory: Early Lung Cancer AssessmentU01CA233370 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., HSU, WILLIAM · 2018 to 2025
$8.0MAdvancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC PatientsUH3CA206126 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIA, DAVID S., SOO HOO, GUY · 2019 to 2021
$1.2MUltra-short circulating tumor DNA (uctDNA) for liquid biopsy of non-small cell lung cancerR21CA239052 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, FENG, WONG, DAVID T · 2019 to 2020
$373kNCI NIH HHS P30 CA016042NCI NIH HHS R21 CA239052NCI NIH HHS U01 CA233370NCI NIH HHS UH3 CA206126
Abstract
PubMed holds no abstract for this paper.
Indexed as
ctDNAEGFRNSCLCosimertinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT02759835ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.